Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effec...
Quotient Limited Announces Reverse Stock Split Effective Today JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split i...
Quotient Limited Announces Intent to Effect Reverse Stock Split JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when ...
A director at Quotient Ltd bought 700,000 shares at 0.200USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Quotient Limited Selected to Join the World Economic Forum New Champions Community The World Economic Forum’s New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better futureThese companies champion new business models and technologies to build resilience into their businesses, industries and communities JERSEY, Channel Islands, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland...
Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies • The National Screening Laboratory of Sanquin Blood Supply Foundation joins MosaiQ Innovator’s Circle JERSEY, Channel Islands, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices (Sanquin), headquartered in Amsterdam, the Netherlands has joined MosaiQ Innovator’s Cir...
Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Di...
Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022...
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu Partnership aims to expand the Transfusion Transmissible Infections, other Infectious Diseases, and clinical diagnostics assay menu on Quotient’s multimodality, multiplexed MosaiQ solution JERSEY, Channel Islands, July 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which...
Quotient Limited Announces Equity Awards JERSEY, Channel Islands, July 01, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Steven Zuiderwijk, who has been appointed as the Chief Strategy & Business Development Officer of the Company effective July 1, 2022. In connection with his appointment, the Company granted Mr. Zuiderwijk 112,780 performance-based restricted share units (PSUs) (the Sign-On PSUs), 67,668 Restricted Share Units (RSUs) (the Sign-On RSUs) and share o...
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants JERSEY, Channel Islands, June 29, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, announced the closing of its previously announced underwritten public offering of 32,458,336 ordinary shares and pre-funded warrants to purchase 34,208,331 ordinary share for aggregate gross proceeds of approximately $20.0 million. The net proceeds to the Company from this offering were approximately $18.5 million, after deducting underwritin...
Quotient Limited Announces Pricing of Underwritten Offering JERSEY, Channel Islands, June 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 66,666,667 ordinary shares and ordinary share equivalents for aggregate gross proceeds of $20.0 million. The aggregate net proceeds to the Company from this offering are expected to be approximately $18.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the C...
Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update Financial Position Amended Secured Notes: Reduces the company’s cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022 MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (...
Quotient Limited Announces Proposed Amendments to Senior Secured Notes Improved debt terms reduces $93 million principal amortization payments over next 36 months JERSEY, Channel Islands, June 23, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the Company), a commercial-stage diagnostics company, today announced that in connection with the public offering announced today, the Company has agreed with the beneficial owners of all $132.9 aggregate principal amount of its 12% Senior Secured Notes due 2025 (the SSNs) to amend the indenture governing the SSNs to: Reduce expected a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.